Zymeworks Inc

Zymeworks Inc. a clinical-stage biopharmaceutical company discovers develops and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include Zanidatamab a human epidermal growth factor receptor 2 (HER2) that is in Phase 1 Phase 2 and Phase 3 clinical trials for the treatment of biliary tract gastroesophageal adenocarcinomas breast colorectal and endometrial cancers; and zanidatamab zovodotin a HER2 -targeted antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology including immuno-oncology agents and other therapeutic areas. The company has strategic partnerships and collaborations with BeiGene Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co. Ltd.; Janssen Biotech Inc.; LEO Pharma A/S; Iconic Therapeutics Inc.; Merck Sharp & Dohme Research GmbH; and Atreca Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver Canada.